Telomere attrition is a risk factor for end-stage liver disease. Due to a lack of adequate models and intrinsic difficulties in studying telomerase in physiologically relevant cells, the molecular mechanisms responsible for liver disease in patients with telomere syndromes remain elusive.
INTRODUCTION
Telomeres are repetitive DNA sequences that prevent degradation and fusion of chromosomal ends. As the DNA replication machinery is unable to fully replicate DNA termini, telomeres become progressively shorter with consecutive cellular divisions, eventually reaching a critical stage where telomere dysfunction induces senescence or cell death 1 . Evidence collected during the past decade has established impaired telomere maintenance as a causative effect in a number of different conditions, ranging from bone marrow failure to pulmonary fibrosis and liver disease 2 . Interestingly, telomere shortening affects different tissues at different ages, and telomere length measurement in hospital settings has recently been proposed as a diagnostic tool in targeted indications, with the potential to inform treatment decisions and influence morbidity 3 .
The active telomerase complex is composed of TERT (reverse transcriptase component), TERC
(the telomerase RNA component), and dyskerin (DKC1), necessary for TERC stabilization 4 .
While mutations in these genes were initially found in children suffering from the bone marrow failure syndrome dyskeratosis congenita (DC), adult-onset phenotypes, such as pulmonary fibrosis and liver disease now represent the most common presentation in patients harboring mutations in telomerase. Interestingly, patients with liver disease usually come to clinical attention at an earlier age and with longer telomeres when compared to patients with pulmonary fibrosis 3 , indicating that liver cells might be more susceptible to telomere dysfunction than the lung epithelia. Liver abnormalities have recently been shown to be common in patients with telomere syndromes, with liver disease carrying important implications for morbidity and mortality in these patients 5 . Accordingly, telomerase deficient mice which underwent ablation of the liver showed impaired hepatocyte regeneration and accelerated development of liver cirrhosis after chronic liver injury 6 . In addition, it has recently been shown that a small population of TERT positive hepatocytes are responsible for hepatocyte renewal and maintenance of liver mass, both in homeostasis and after critical injury 7 . While these results highlight the importance of telomerase for hepatocyte regeneration and liver disease, the chain of events linking telomere shortening to hepatocyte and liver failure in humans remains elusive. In fact, while genetic mutations in telomerase have been associated with different liver diseases, ranging from nonalcoholic fatty liver disease and non-alcoholic steatohepatitis to fibrosis and cirrhosis, the mechanisms behind liver tissue reorganization and failure in settings of dysfunctional telomeres
have not yet been elucidated 8, 9 . A major hurdle to address this question has been a lack of viable models to specifically analyze the impact of exacerbated telomere shortening in human hepatocytes. To overcome this limitation, we used the targeted differentiation of human embryonic stem cells (hESCs) into mature, hepatocyte-like cells. We used wild-type (H1 hESC line) and CRISPR/cas9 isogenic engineered hESCs harboring a clinically relevant mutation in telomerase (DKC1_A353V mutants created by introduction of a 1058C>T point mutation in the DKC1 gene 10 ). The engineered cells are free of detectable chromosomal abnormalities by Gband analysis and are pluripotent, but have reduced telomerase activity and progressive telomere shortening due to low levels of TERC expression (Supplemental Figure 1A -G). Gene Editing. DKC1_A353V and DKC1_A353V_p53 -/-, were generated using CRISPR/Cas9 genome editing technology and are described in detail in 9 . In brief, CRISPR gRNAs were inserted into the MLM3636 plasmid (Addgene 43860) and co-transfected with a plasmid carrying Cas9 (Addgene 43945) using the 4D-Nucleofector with the P4 Primary Cell 4D-Nucleofector kit (Lonza, Allendale, NJ). Single-stranded DNA donor oligos were co-transfected with plasmids carrying specific gRNAs and Cas9. For DKC1_A353V_p53 -/-, one gRNA sequence was co-transfected with Cas9 to induce non-homologous end-joining (NHEJ) resulting in a frame shift and early termination, which was verified by targeted sequencing and protein expression analysis. Nucleofected cells were seeded on matrigel at low density and manually picked when colonies reached an appropriate size. Clones were then screened and sequenced.
METHODS
DKC1_A353V+TERC, and DKC1_A353V_shHNF4α hESCs were generated by zinc finger nuclease (ZFN). Transfection targeting the AAVS1 locus was performed with X-TremeGene 9
following the manufacturer's instructions (Roche, Indianapolis, IN).
Hepatocyte differentiation. Differentiation of hESCs into hepatocyte-like cells was performed according to 10 . Briefly, hESCs were transferred to a 100 mm plate coated with matrigel and incubated at 37°C in 5% CO 2 and 5% O 2 for 3 days or until 90-95% confluent. β -actin was used as the reference loading gene. All primer sequences can be found in (Supplemental Table 1 ).
Caspase Activity Measurement. Caspase activity was quantified using dedicated Caspase 3, 8, and 9 colorimetric detection kits following manufacturer's instructions (Abcam).
RESULTS

Telomerase is quickly down-regulated during hepatocyte differentiation from hESCS
Our in vitro hepatic-derivation protocol from hESCs (adapted from 11 ) recapitulates different hepatocyte development stages including endoderm (day 6; CXCR4, SOX17 positive cells), hepatic endoderm (day 11; HNF4α positive cells), immature hepatocytes (day 16; AFP positive cells) and finally mature, hepatocyte-like cells (day 21) that express FGA, FGG, CYP1A1 and albumin ( Figure 1A -B). Recapitulating in vivo data, telomerase activity is quickly downregulated during the initial stages of differentiation ( Figure 1C ), due to the specific silencing of TERT expression, as TERC levels remain unaltered ( Figure 1D ). Importantly, despite the fast silencing of telomerase, telomeres are not significantly shortened during the 21 days of hepatic differentiation ( Figure 1E ), indicating that the initial telomere length at Day 1 of differentiation can be used as a reference for observed phenotypes during the entire, 21 days, hepatocyte maturation protocol.
Progressive telomere shortening impairs hepatocyte development
Combining our genetically engineered DKC1_A353V hESCs with this in vitro hepatocyte differentiation protocol, we were able to study hepatocyte development in clinically relevant telomerase mutant cells with progressively shorter telomeres. We chose two different stages, DKC1_A353V cells with longer telomeres (referred to as early passage -EP; passage <13) and shorter telomeres (referred to as late passage -LP; passage >30; Supplemental Figure 1G 
Stabilization of p53 reduces hepatocyte differentiation from DKC1_A353V hESCs
As telomere shortening is a known inducer of senescence and cell death, we next decided to understand if the failure to form hepatic endoderm in our DKC1_A353V hESCs with short telomeres was a consequence of reduced cellular viability. Indeed, we verified that during hepatocyte differentiation of DKC1_A353V_LP hESCs, there is accrual of DNA damage (as measured by γH2AX accumulation) and stabilization of p53 ( Figure 3A) , both of these common responses of telomere shortening and dysfunction in mammalian cells. Surprisingly however, our data indicates that the reduced hepatocyte specification observed in DKC1_A353V_LP cells was not caused by apoptosis activation ( Figure 3B ) or reduced cellular proliferation ( Figure 3C ).
In fact, while DKC1_A353V_LP are unable to differentiate into hepatocyte-like cells ( Figure   2D -G), overall cellular proliferation was significantly increased in DKC1_A353V_LP cells during the 21 days of differentiation ( Figure 3C ). This indicates that telomere shortening specifically impairs hepatocyte development through a mechanism that is independent from its well established role in cell death and/or cell cycle arrest.
We therefore decided to probe if the observed p53 up-regulation during the hepatocyte differentiation of DKC1_A353V_LP hESCs cells ( Figure 3A ) was a determinant factor in the reduced efficiency of hepatocyte development observed in cells with short telomeres. For that we used DKC1_A353V_LP hESCs where we ablated p53 through genome engineering (CRISPR/cas9) 10 . These DKC1_A353V_p53 -/-hESCs retain short telomeres, as telomerase is still defective, but have no activation of p53-dependent signaling 10 . Interestingly, although retaining short telomeres, these cells have normal hepatocyte differentiation capacity, with restored levels of HNF4α expression during the hepatic endoderm stage ( Figure 3D ) and restored expression of hepatocyte markers ( Figure 3E ). Likewise, there is a significant increase in the number of albumin positive cells at the mature hepatocyte-like cells stage ( Figure 3F ).
Collectively, these data indicate that the activation of p53 by telomere shortening specifically impairs hepatocyte development from hESCs.
Restoring HNF4α successfully rescues hepatocyte derivation and function in telomerase mutant cells
As the earliest phenotype observed during the hepatic differentiation of DKC1_A353V hESCs with short telomeres was reduced hepatic endoderm formation, we focused more deeply on that developmental stage. Specifically, we hypothesized that the marked reduction in HNF4α In our in vitro differentiation system we verified that HNF4α expression in WT cells increases continuously until day 11 of differentiation ( Figure 4A ). Moreover, the silencing HNF4α in WT cells by constitutive expression of short-hairpin RNA sequences from the AAVS1 locus (Supplemental Figure 3) , causes a significant reduction in hepatic differentiation ( Figure 4B) , similar to what we observe in DKC1_A353V_LP cells. Therefore, to confirm that the reduced expression of HNF4α was responsible for the reduced hepatic differentiation observed in DKC1_A353V_LP cells, we again used genome engineering to conditionally express (in a DOXinducible system; Figure 4C , inlet) HNF4α in late passage DKC1_A353V cells. Surprisingly, the expression of HNF4α in cells that retain short telomeres ( Figure 4C ) is able to rescue hepatic differentiation ( Figure 4D ) and function ( Figure 4E ). Moreover, expression of HNF4α prevents the increased cellular proliferation observed in cells with dysfunctional telomeres ( Figure 4F ).
Combined, this data indicates that restoring HNF4α levels successfully overcomes the deleterious consequences of telomere dysfunction observed during hepatocyte development.
CONCLUSIONS
Combined, our data clearly establishes HNF4α levels as a major determinant of hepatic differentiation in settings of short telomeres and provides insight on the mechanism behind the severe hepatocyte failure observed in patients with telomere syndromes. As low levels of HNF4α are commonly found in liver disease, our data indicates that p53 mediated silencing of HNF4α could be linked to disease onset in patients with defective telomere maintenance and, therefore, potential therapies aiming at restoring HNF4α levels in these patients could prove beneficial. In this regard, while further analysis is necessary to decipher the specific mechanism of HNF4α silencing by p53, our in vitro differentiation platform provides a robust platform for n=3, mean ± SEM, *p≤0.05; **p≤0.0025; ****p≤0.0001. Statistical analysis was performed using one-way ANOVA followed by Tukey's post hoc test. 
